Regeneron Pharmaceuticals, Inc. (REGN)
Nasdaq: REGN · Pharmaceutical Preparations · Tarrytown, NY · filing with the SEC since 1995
Grade7.3
◀ Past 7.9● Present 8.5▶ Future 5.0
Who owns Regeneron Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
1
Vanguard Capital Management holds 7.37% of Common Stock, as its SCHEDULE 13G filed Apr 30, 2026 says.
Directors and officers
19
report now, of 27 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed Jun 5, 2025 · Common Stock - par value $.001 per share · reported falling below 5%, from 5.1% in Apr 22, 2025
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2025 · COMMON STOCK · reported falling below 5%, from 7.6% in Feb 12, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What REGN reports owning in othersstakes of 5% or more, and other ties
30 subsidiaries in 14 countries, from the list filed with the 10-K filed Feb 4, 2026. Its Form 13F-HR for Jun 30, 2026 lists 3 holdings. The record carries no value for them.
Insider tradesForm 4
135sales
0purchases
107sales on a scheduled plan
11people selling
$58.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Sing George L | director | 9 | $20.4M | 0 | 0 | $0 |
| Zoghbi Huda Y | director | 14 | $9.1M | 12 | 0 | $0 |
| Poon Christine A | director | 6 | $7.6M | 0 | 0 | $0 |
| Pitofsky Jason | SVP Controller | 20 | $5.7M | 11 | 0 | $0 |
| Larosa Joseph J | EVP General Counsel and Secret | 2 | $4.3M | 0 | 0 | $0 |
| Murphy Andrew J | Co-Chief Scientific Officer | 27 | $3.2M | 27 | 0 | $0 |
| Mccourt Marion | EVP Commercial | 3 | $3.0M | 3 | 0 | $0 |
| Bassler Bonnie L | director | 2 | $1.8M | 2 | 0 | $0 |
| Brown Michael S | director | 1 | $1.7M | 1 | 0 | $0 |
| Guarini Kathryn | director | 3 | $1.0M | 3 | 0 | $0 |
| Ryan Arthur F | director | 48 | $400,000 | 48 | 0 | $0 |